146 related articles for article (PubMed ID: 38053355)
1. Therapeutic Potential of Targeting Transforming Growth Factor-beta (TGF-β) and Programmed Death-ligand 1 (PD-L1) in Pancreatic Cancer.
Pourali G; Zafari N; Velayati M; Mehrabadi S; Maftooh M; Hassanian SM; Mobarhan MG; Ferns GA; Avan A; Khazaei M
Curr Drug Targets; 2023; 24(17):1335-1345. PubMed ID: 38053355
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor-β signalling in tumour resistance to the anti-PD-(L)1 therapy: Updated.
Mortezaee K; Majidpoor J
J Cell Mol Med; 2023 Feb; 27(3):311-321. PubMed ID: 36625080
[TBL] [Abstract][Full Text] [Related]
3. Dual targeting of TGF-β and PD-L1 inhibits tumor growth in TGF-β/PD-L1-driven colorectal carcinoma.
Khalili-Tanha G; Fiuji H; Gharib M; Moghbeli M; Khalili-Tanha N; Rahmani F; Shakour N; Maftooh M; Hassanian SM; Asgharzadeh F; Shahidsales S; Anvari K; Mozafari MR; Ferns GA; Batra J; Giovannetti E; Khazaei M; Avan A
Life Sci; 2023 Sep; 328():121865. PubMed ID: 37336360
[TBL] [Abstract][Full Text] [Related]
4. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses.
Lan Y; Yeung TL; Huang H; Wegener AA; Saha S; Toister-Achituv M; Jenkins MH; Chiu LY; Lazorchak A; Tarcic O; Wang H; Qi J; Locke G; Kalimi D; Qin G; Marelli B; Yu H; Gross AW; Derner MG; Soloviev M; Botte M; Sircar A; Ma H; Sood VD; Zhang D; Jiang F; Lo KM
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858707
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial Disruption Nanosystem Simultaneously Depressed Programmed Death Ligand-1 and Transforming Growth Factor-β to Overcome Photodynamic Immunotherapy Resistance.
Jiang X; Yi L; Li C; Wang H; Xiong W; Li Y; Zhou Z; Shen J
ACS Nano; 2024 Jan; 18(4):3331-3348. PubMed ID: 38227812
[TBL] [Abstract][Full Text] [Related]
6. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances.
Lind H; Gameiro SR; Jochems C; Donahue RN; Strauss J; Gulley JL; Palena C; Schlom J
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32079617
[TBL] [Abstract][Full Text] [Related]
7. Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression.
Hussain SM; Kansal RG; Alvarez MA; Hollingsworth TJ; Elahi A; Miranda-Carboni G; Hendrick LE; Pingili AK; Albritton LM; Dickson PV; Deneve JL; Yakoub D; Hayes DN; Kurosu M; Shibata D; Makowski L; Glazer ES
Cell Oncol (Dordr); 2021 Jun; 44(3):673-687. PubMed ID: 33694102
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.
Gulley JL; Schlom J; Barcellos-Hoff MH; Wang XJ; Seoane J; Audhuy F; Lan Y; Dussault I; Moustakas A
Mol Oncol; 2022 Jun; 16(11):2117-2134. PubMed ID: 34854206
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
10. Dual anti-PD-(L)1/TGF-β inhibitors in cancer immunotherapy - Updated.
Karami Z; Mortezaee K; Majidpoor J
Int Immunopharmacol; 2023 Sep; 122():110648. PubMed ID: 37459782
[TBL] [Abstract][Full Text] [Related]
11. TGF-β Alters the Proportion of Infiltrating Immune Cells in a Pancreatic Ductal Adenocarcinoma.
Trebska-McGowan K; Chaib M; Alvarez MA; Kansal R; Pingili AK; Shibata D; Makowski L; Glazer ES
J Gastrointest Surg; 2022 Jan; 26(1):113-121. PubMed ID: 34260016
[TBL] [Abstract][Full Text] [Related]
12. Exploring novel systemic therapies for pancreatic cancer: a review of emerging anti-PD-1/PD-L1 combination therapy.
Zhang H; Duan XR; Xing LY; Jia YX; Zhou JY; Ma JJ
Neoplasma; 2022 Sep; 69(5):995-1007. PubMed ID: 35786997
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer.
Funaki S; Shintani Y; Kawamura T; Kanzaki R; Minami M; Okumura M
Oncol Rep; 2017 Oct; 38(4):2277-2284. PubMed ID: 28849209
[TBL] [Abstract][Full Text] [Related]
14. An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-β with enhanced antitumor efficacies.
Fan W; Chen Y; Zhou Z; Duan W; Yang C; Sheng S; Wang Y; Wei X; Liu Y; Huang Y
Int Immunopharmacol; 2024 Mar; 130():111698. PubMed ID: 38377856
[TBL] [Abstract][Full Text] [Related]
15. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
[TBL] [Abstract][Full Text] [Related]
16. Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1-mediated tumor eradication.
Horn LA; Chariou PL; Gameiro SR; Qin H; Iida M; Fousek K; Meyer TJ; Cam M; Flies D; Langermann S; Schlom J; Palena C
J Clin Invest; 2022 Apr; 132(8):. PubMed ID: 35230974
[TBL] [Abstract][Full Text] [Related]
17. IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1.
Eriksson E; Milenova I; Wenthe J; Moreno R; Alemany R; Loskog A
J Immunol; 2019 Feb; 202(3):787-798. PubMed ID: 30617223
[TBL] [Abstract][Full Text] [Related]
18. Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy.
Rouzbahani E; Majidpoor J; Najafi S; Mortezaee K
Biomed Pharmacother; 2022 Dec; 156():113906. PubMed ID: 36306594
[TBL] [Abstract][Full Text] [Related]
19. Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer.
Enkhbat T; Nishi M; Takasu C; Yoshikawa K; Jun H; Tokunaga T; Kashihara H; Ishikawa D; Shimada M
Anticancer Res; 2018 Jun; 38(6):3367-3373. PubMed ID: 29848685
[TBL] [Abstract][Full Text] [Related]
20. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
